Yabao pharmaceutical: accelerate the overseas distribution of products and become a "child health expert"

[China Pharmaceutical network enterprise news] recently, Yabao pharmaceutical announced that it has received the natural health product marketing license issued by the health department of Canada, and Yabao dinggui'er navel sticker has obtained the qualification to sell in the Canadian market What's the strategic significance of this for the future development of Yabao pharmaceutical? Recently, Ren Wuxian, chairman of Yabao pharmaceutical, said in an interview with Xinhuanet that Yabao's goal is to become a "child health expert" Obtaining the Canadian listing license for Ding gui'er's umbilicus sticker is a key step for the company to promote the international strategy of "one place for research and development, three places for approval; one place for production and three places for sales" The next goal is to get the certification of production line as soon as possible in summer, and then to the high incidence season of gastrointestinal diseases in infants Baby catch cold or eat bad, easy to cause diarrhea, many families are often prepared Ding gui'er umbilical patch to deal with baby diarrhea As a product of the company, dinggui'er navel patch is a new transdermal drug delivery preparation developed by Yabao Pharmaceutical Co., Ltd This medicine is composed of clove, cinnamon and Piper longum, which are used to treat diarrhea and abdominal pain in children Drug molecules enter the body through the navel, which not only helps to avoid the stimulation of oral drugs on gastrointestinal tract and the influence on digestive function, but also saves the parents' worries about drug feeding Ren Wuxian said that in order to make the efficacy of each patch uniform, Yabao pharmaceutical uses advanced modern extraction technology of traditional Chinese medicine, as well as the fully automatic production line of traditional Chinese medicine patch customized from Germany At the same time, Yabao pharmaceutical also established a domestic professional "transdermal drug delivery technology innovation research team" and "Shanxi Provincial Key Laboratory of transdermal drug delivery system" based on "dinggui'er umbilical patch" "Dinggui'er navel sticker has been listed for 25 years This time, it has obtained the listing license in Canada, which is of great significance for the company to continuously implement the international strategy of" one place for research and development, three places for approval, one place for production and three places for sales " Ren said the next goal is to get Canadian certification for Ding gui'er's umbilical patch production line in China as soon as possible After dinggui'er navel paste officially enters the Canadian market, it is expected to drive more Chinese medicine products of the company to go overseas, so as to realize the international layout of "R & D in China, application in the United States, Europe and China; production in China, sales in the United States, Europe and China" To create excellent pediatric drugs, we should adhere to the "13th five year" health and health plan, and strengthen the basic drug use guarantee for children According to the data released by the National Bureau of statistics, in 2017, China's birth population reached 17.23 million, with a birth rate of 12.43 ‰, indicating a promising market for paediatric drugs However, many families are still troubled by the current situation of children's medicine "drug use depends on breaking, dose depends on guessing" In recent years, the state attaches great importance to the safety of children's drug use, and the R & D and approval procedures for children's drug use continue to speed up, which is a major good policy for the development of industries and enterprises However, the requirements of children's drug use are stricter, the cost of research and development is high, the difficulty of clinical trials is large, and the profit space is small, which leads to the low enthusiasm of some enterprises, which is also an objective phenomenon " Ren Wuxian said that Yabao pharmaceutical has always taken the development of children's drug use as an important strategy for the development of enterprises for many years On the one hand, it is based on market efficiency, and on the other hand, it is also considered that enterprises should shoulder greater social responsibility "To be a leader in the field of children's health and an expert in children's health" is one of the strategic goals of Yabao pharmaceutical during the 13th Five Year Plan period Ren Wuxian said that in order to achieve this goal, the enterprise persisted in strives for perfection, with ingenuity and good medicine, and continued to invest in developing more Chinese medicine products and chemical generic products suitable for children In 2016, it introduced the pediatric digestive product Coix bud Jianpi gel, and in 2017, its children's Qingyan heat clearing oral liquid was included in the new version of the national health insurance directory He also said that in the future, the big health industry around children's medicine will be a bigger market focused by enterprises In addition to children's medicine, Yabao pharmaceutical's R & D and innovation in cardiovascular, cerebrovascular, endocrine, tumor and other diseases are also bright spots According to the company, Yabao pharmaceutical has established technical cooperation with internationally renowned pharmaceutical companies and research institutes such as Eli Lilly pharmaceutical, the Department of science and technology of National Academy of medicine, Rosen Health Research Institute of Canada, University of South Australia, etc., to jointly develop a variety of innovative drugs for diabetes, Parkinson's disease, sepsis, stroke and other diseases At present, the company has 10 innovative drugs under research, 2 of which have entered the clinical practice, and 2 have been accepted by the clinical practice "In 2017, Yabao's R & D expenses accounted for 7.11% of the total sales revenue This year, Yabao will continue to increase the investment in R & D expenses, which includes not only the development of innovative drugs, but also the evaluation of the quality and efficacy consistency of generic drugs." Ren Wuxian pointed out that innovation driven development, in the future, Yabao pharmaceutical will deepen its industry while leveraging capital to achieve faster and better development of enterprises through endogenous "asset management" and extended "capital operation" Former title: Ren Wuxian, chairman of Yabao Pharmaceutical Co., Ltd.: accelerating the overseas distribution of products and becoming a "child health expert" reporter: Yuan Xinchen